Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
about
Bortezomib for the treatment of mantle cell lymphoma: an updateOutcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature reviewLenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.Bortezomib in mantle cell lymphoma: comparative therapeutic outcomesPhase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.Non-Hodgkin's lymphomas, version 4.2014.Bortezomib for the treatment of non-Hodgkin's lymphomaCurrent regimens and novel agents for mantle cell lymphoma.Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.Ibrutinib in B lymphoid malignancies.Bortezomib in the treatment of mantle cell lymphoma.Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.Ibrutinib for mantle cell lymphoma.Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.Novel agents in mantle cell lymphoma.Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randCurrent overview and treatment of mantle cell lymphoma
P2860
Q26738940-B9CAEF94-5AA5-4D55-80F3-DB35CFA0BBC0Q28087748-651D87E6-6710-43DB-B4FB-41B8EC01BD49Q33427312-0DFECAD5-2E16-47DC-BCC2-E0BF7388C887Q36278006-538AE089-651D-4DCB-8C30-68B49B438291Q36456078-9F05C520-3805-40EC-B4CB-A49845BE8759Q36820885-F28A8C29-D02B-435B-B5BA-5B9FF403DBAAQ36868056-82B8AC7A-B704-4EFB-95B7-C6F8A830CB24Q38224186-B7D0B577-5422-43E8-A957-D33D81F572CDQ38480491-C2F15E0E-C55B-440B-94A4-D1A0C70A24A5Q38530254-66FC8A45-1063-4862-B95E-B0B0F48D1927Q38532268-F8063725-9BB5-4D68-A424-B989CEB8B216Q38538693-267FE8A3-A7BA-458B-A279-80AC820B50CEQ38545545-98FE51BE-01FE-4F11-88D4-309C9CE681FBQ38582650-1369EBC5-6757-42D5-B92A-C92BC1B574A7Q38667361-473D2C7F-6107-4FD7-AA83-D9F68F9E61A9Q38694168-3F28D762-2A49-44E7-9512-DBA10D53DA31Q39045701-85D29010-C889-4658-9CF3-91A72E32857AQ39175963-3620EBEF-CDE1-4AA2-924C-29A1A77F2D85Q39290199-991EAEBC-D801-45BB-9744-E32BA50CAFF7Q44679554-4C2430E3-9EA1-4142-BD0F-5E82684C4E15Q47886065-8326F507-CC23-40EC-88F6-A11A419C113FQ48546805-71DA607D-86D5-4F7F-886C-15BB0E36FE68Q50025694-164433FE-8C6C-4F75-9F72-57A2A8230EC0Q57174710-826313CA-86EB-4228-BFD8-A48A4CD76950
P2860
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase 2 study of VcR-CVAD with ...... Oncology Group study (E1405).
@en
Phase 2 study of VcR-CVAD with ...... operative Oncology Group study
@nl
type
label
Phase 2 study of VcR-CVAD with ...... Oncology Group study (E1405).
@en
Phase 2 study of VcR-CVAD with ...... operative Oncology Group study
@nl
prefLabel
Phase 2 study of VcR-CVAD with ...... Oncology Group study (E1405).
@en
Phase 2 study of VcR-CVAD with ...... operative Oncology Group study
@nl
P2093
P2860
P1433
P1476
Phase 2 study of VcR-CVAD with ...... Oncology Group study (E1405).
@en
P2093
Brad S Kahl
David T Yang
Elisabeth M Paietta
Julie E Chang
Mitchell R Smith
Ranjana H Advani
Sandra J Horning
P2860
P304
P356
10.1182/BLOOD-2013-08-523845
P407
P577
2014-01-23T00:00:00Z